Lilly climbs after obesity drug reduces weight by 28.7% in late-stage osteoarthritis trial

Shares of U.S. drugmaker Eli Lilly LLY.N rise 2.7% to $1,018.5 premarket

Lilly says its next-generation experimental obesity drug retatrutide helped patients with obesity and knee osteoarthritis lose an average of 28.7% of their weight in a late-stage trial

In its first late-stage trial, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from a deep aching joint pain

Lilly says seven additional late-stage trials evaluating the drug in obesity and type 2 diabetes are expected to be completed in 2026

Up to last close, LLY was up 28.7% YTD